Category: Side Effect: Cardiovascular (heart attack, stroke, heart failure, PE, DVT)
-
Denosumab Drugs Prolia And Xgeva Linked To QT Interval Prolongation Associated With Hypocalcemia
Australia's Drug Regulator Issues Warnings And Mandates Label Changes, Following Similar Action In Europe; Will FDA Follow Thess Leads? (Posted by Tom Lamb at DrugInjuryWatch.com) In early August 2016 we learned about…
-
Possible Linzess Recall By FDA Suggested By Phase Five Research Analyst Report, Which Has Become A Bit Of A Mystery
Here Are Some Of The "Findings" From An April 26, 2016 Document Which Seems To Have Disappeared Only Two Days Later (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: "Synergy Petitions FDA…
-
Possible Linzess Recall By FDA Suggested By Phase Five Research Analyst Report, Which Has Become A Bit Of A Mystery
Here Are Some Of The "Findings" From An April 26, 2016 Document Which Seems To Have Disappeared Only Two Days Later (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: "Synergy Petitions FDA…
-
Onglyza, Nesina, And Similar Diabetes Drugs Get FDA Drug Safety Warnings About Risk Of Heart Failure Side Effect
Set Of Newer Diabetes Medications Containing Saxagliptin And Alogliptin Also Being Investigated By FDA For Increased Risk Of Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On April 5, 2016 the FDA…
-
Onglyza, Nesina, And Similar Diabetes Drugs Get FDA Drug Safety Warnings About Risk Of Heart Failure Side Effect
Set Of Newer Diabetes Medications Containing Saxagliptin And Alogliptin Also Being Investigated By FDA For Increased Risk Of Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On April 5, 2016 the FDA…
-
Farxiga / Invokana / Jardiance: Reports Of Stroke, DVT, Pulmonary Embolism, And Kidney Damage Being Investigated By FDA, But No Label Changes, Yet
Two "Potential Signals of Serious Risks/New Safety Information Identified By FAERS" Reports From 2015 Were Not Made Public By FDA Until February – March 2016 (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE:…
-
Bayer’s Corporate Reports About Their YAZ / Yasmin Settlement Program Show Progress Continues To Be Made, Albeit At A Slow Pace
First Lawsuits In The YAZ / Yasmin / Gianvi / Ocella / Beyaz / Safyral Drug Injury Litigation Were Filed In 2009, With Thousands Of Cases Still Pending (Posted by Tom Lamb at…
-
In The Shadow Of Recent Announcement About Diabetes Drug Jardiance Medical Study Results There Lingers Safety Concerns For SGLT-2 Inhibitors
As With Invokana and Farxiga, Jardiance Is Subject Of Several Drug Regulatory Agency Investigations About Ketoacidosis And Other Side Effects (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE: “Health Canada Warns About Link…
-
Will There Be Another Drug Label Change For YAZ And Other Drospirenone (DRSP) Birth Control Pills, As FDA Required For Ortho Evra Years Ago
Since Bayer Revised YAZ Label In April 2012 There Has Been More Medical Evidence That DRSP Pills Increase Risks Of Blood Clot Side Effects Like DVT And PE (Posted by Tom Lamb at…